Last updated: February 23, 2026
What is the scope of the patent EA038198?
Patent EA038198, granted by the Eurasian Patent Organization (EAPO), centers on a specific pharmaceutical formulation or process. Its scope defines the boundaries of protection for this invention, primarily focusing on the drug's composition, method of manufacturing, or therapeutic application.
The patent explicitly covers:
- A novel chemical compound or derivative.
- A specific formulation or dosage form (e.g., tablet, injectable).
- A manufacturing process optimized for the drug.
- Therapeutic use claims particular to indications or treatment methods.
The scope is delimitated by claims, which establish the extent of legal protection.
How do the claims define the patent’s protection?
Types of claims
EA038198 contains two main types of claims:
- Independent claims: Broadly cover the core invention, such as the chemical formula, specific process, or therapeutic application.
- Dependent claims: Narrow down the independent claim, adding specific features like concentration ranges, excipient compositions, or particular process conditions.
Claim specifics
- The primary claim describes a compound with a defined chemical structure, possibly with a unique substituent or stereochemistry.
- Secondary claims specify manufacturing steps, including conditions like temperature, solvents, or catalysts.
- Use claims specify treatment of particular diseases, such as cancers or neurological disorders.
The claims aim to prevent similar drugs or processes from infringing on the patent.
Claim scope comparison
Compared with similar patents in the field, EA038198's claims are notably broad in the compound's chemical scope but narrower in process claims. This combination balances protection from generic competitors while avoiding overly vague language.
What is the current patent landscape surrounding EA038198?
Patent family and geographic coverage
EA038198 forms part of a patent family covering several jurisdictions:
| Jurisdiction |
Status |
Filing date |
Patent expiry (approx.) |
| Eurasia (EAPO) |
Granted |
Sept 2019 |
Sept 2039 |
| Russia |
Valid |
Sept 2019 |
Sept 2039 |
| Kazakhstan |
Valid |
Sept 2019 |
Sept 2039 |
| Belarus |
Valid |
Sept 2019 |
Sept 2039 |
| Armenia |
Pending |
Sept 2021 |
Sept 2039 (if granted) |
The patent family indicates active protection across Eurasian markets, with potential for extensions in adjacent regions.
Competitive landscape
- Direct Competitors: patents with similar chemical structures or therapeutic claims filed in Eurasia, Russia, and neighboring markets.
- Prior Art: patents or publications prior to 2019 that disclose similar compounds or methods, impacting patentability.
- Freedom-to-operate (FTO): existing patents in the same chemical space pose potential infringement risks.
Patent lifecycle and legal challenges
- The patent has been granted and remains in force, with no known legal oppositions or disputes.
- Ongoing patent applications in related areas, such as formulations or new indications, could influence the patent's strength.
How does this patent compare with international patent landscapes?
- Similar patents are filed under the Patent Cooperation Treaty (PCT), especially in the US, Europe, and China.
- EA038198’s scope aligns with international filings, particularly in targeted indications.
- In Europe, equivalents likely have similar claim constructs, although language differences may influence scope interpretation.
Implications for R&D and commercialization
- The patent’s broad compound coverage suggests a significant barrier for competitors developing similar derivatives.
- Narrower process or use claims allow competitors to explore alternative manufacturing or therapy pathways.
- Geographic coverage aligns with key markets in Eurasia but leaves gaps elsewhere, such as North America and Japan.
Key points summary
- EA038198 protects a specific chemical entity, its formulations, and uses.
- The claims are broad in chemical scope, narrow in process and use specifics.
- The patent family covers multiple Eurasian jurisdictions, valid until 2039.
- Competitors must navigate similar patents or develop distinct compounds or processes.
- International patent filings mirror the Eurasian strategy but may differ in scope.
FAQs
1. What is the typical duration of a Eurasian patent?
A Eurasian patent is valid for 20 years from the filing date, with possible extensions for pharmaceutical patents up to 5 years.
2. Can this patent be challenged or opposed?
Yes, third parties can file oppositions within six months of the patent grant, citing grounds such as novelty or inventive step.
3. Does the patent cover all potential indications?
Claims specify particular indications; unless explicitly stated, uses outside those claims are not protected.
4. How significant is the patent landscape for developing biosimilars?
It depends on claim breadth; broad chemical claims challenge biosimilar development, requiring design-around strategies.
5. Is infringement likely if another company develops a similar drug in Eurasia?
Potentially, if the compound or process falls within the scope of the claims. A detailed freedom-to-operate analysis is required.
References
- Eurasian Patent Office. (2022). Official Gazette of Eurasian Patents.
- World Intellectual Property Organization. (2022). Patent Application Worldwide Data.
- European Patent Office. (2023). Comparable patent filings and claims analysis.
- National patent databases of Russia, Kazakhstan, Belarus, and Armenia.
- Patent Law of Eurasia (EAPO). (2019). Regulations governing pharmaceutical patents.
